

FORM PTO-1449

This 1449 is ID to the one
for 08/445616 LT
LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.

943-3

Serial No.

08/447,292

Applicant

Clark et al.

Filing Date

22 May 1995

Group

Not assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
LT	1	4,876,242	24.10.89	Applebaum, J.	514	3	
LT	2	4,988,675	29.01.91	Froesch et al.	514	4	
LT	3	5,068,224	26.11.91	Fryklund et al.	514	21	
LT	4	5,093,317	03.03.92	Lewis et al.	514		
LT	5	5,106,832	21.04.92	Froesch et al.	514	12	
LT	6	5,126,324	30.06.92	Clark et al.	514	3	
LT	7	5,187,151	16.02.93	Clark et al.	514	12	
LT	8	5,202,119	13.04.93	Clark et al.	514	3	
LT	9	5,273,961	28.12.93	Clark	514	3	
LT	10	5,374,620	20.12.94	Clark et al.	514	12	04.06.93

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
LT	11	WO 91/03253	21.03.91	PCT				
LT	12	WO 92/11865	23.07.92	PCT				
LT	13	WO 93/23071	25.11.93	PCT				
LT	14	WO 94/16722	04.08.94	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

LT	15	Baxter, "The somatomedins: insulin-like growth factors" <u>Advances in Clinical Chemistry</u> 25:49-115 (1986)
LT	16	Binoux, M., "Donnees recentes sur les somatomedines" <u>Annales d'Endocrinologie</u> 41:157-191 (1980)
LT	17	Chen et al., "Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation" <u>US Endocrine Meeting (Abstract 1596)</u> pps. 449 (1993)
LT	18	Clemmons and Van Wyk, "Somatomedin: physiological control and effects on cell proliferation" <u>Handbook Exp. Pharmacol.</u> 57:161-208 (1981)
LT	19	Cohick and Clemons, "The insulin-like growth factors" <u>Annu. Rev. Physiol.</u> 55:131-153 (1993)
LT	20	Duerr et al., "Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure" <u>J. Clin. Invest.</u> 95:619-627 (1995)
LT	21	Elahi et al., "Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men" <u>Modrn Concepts of Insulin-Like Growth Factors</u> , Spenser, ed., New York:Elsevier Science Publ. Co. pps. 219-224 (1991)
LT	22	Guler et al., "Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects" <u>Proc. Natl. Acad. Sci. USA</u> 86:2868-2872 (April 1989)
LT	23	Guler et al., "Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man" <u>Acta Endocrinologica</u> 121:101-106 (1989)
LT	24	Guler et al., "Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats" <u>Proc. Natl. Acad. Sci. USA</u> 85:4889-4893 (1988)

Examiner	Date Considered
<i>Patty Dexxaw Pts</i>	17 4-26-96

*Examiner: Initial if reference considered; whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.

943-3

Serial No.

08/447,292

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

May 13 1995
PTO-1449

Applicant

Clark et al.

Filing Date

22 May 1995

Group

Not assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

LT	25	Guler et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults" <u>New England J. of Medicine</u> 317(3):137-140 (1987)
LT	26	Hammerman, "Ask the expert: What are the clinical uses of IGF I in acute and chronic renal failure?" <u>Ped. Nephrology</u> 8:544 (1994)
LT	27	Hammerman and Miller, "The growth hormone insulin-like factor axis in kidney revisited" <u>Am. J. Physiol.</u> 265:F1-F14 (1993)
LT	28	Hammerman and Miller, "Therapeutic use of growth factors in renal failure" <u>J. Am. Soc. Nephrol.</u> 5:1-11 (1994)
J	29	Hirschberg et al., "Effects of insulin-like growth factor I on renal function in normal men" <u>Kidney International</u> 43:387-397 (1993)
LT	30	Hise et al., "Influence of circulating insulin-like growth factor-I compared with that of intrarenal insulin-like growth factor-I on proximal nephron receptor density in rats" <u>Clinical Science</u> 83:233-239 (1992)
LT	31	Hoogenberg et al., "Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency" <u>Acta Endocrinologica</u> 129:151-157 (1993)
LT	32	Ikkos et al., "Glomerular filtration rate and renal plasma flow in acromegaly" <u>Acta Endocrinologica</u> 21:226-236 (1956)
LT	33	Jabri et al., "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients" <u>Diabetes</u> 43:369-374 (1994)
LT	34	Kanety et al., "Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity" <u>Acta Endocrinologica</u> 128:144-149 (1993)
LT	35	Kerr et al., "Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans" <u>J. Clin. Invest.</u> 91:141-147 (1993)
LT	36	Kupfer et al., "Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously" <u>J. Clin. Invest.</u> 91:391-396 (1993)
LT	37	Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia" <u>US Endocrine Meeting</u> (Abstract 1664) pps. 466 (1993)
LT	38	Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome" <u>J. Clin. Endocrinol. and Metab.</u> 78(2):404-410 (1994)
LT	39	Lieberman et al., "Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans" <u>J. Clin. Endocrinol. and Metab.</u> 75(1):30-36 (1992)
LT	40	Miller et al., "Effects of IGF-I on renal function in end-stage chronic renal failure" <u>Kidney Int.</u> 46:201-207 (1994)
LT	41	O'Shea and Layish, "Growth hormone and the kidney: a case presentation and review of the literature" <u>J. Am. Soc. Nephrol.</u> 3:157-161 (1992)
LT	42	O'Shea et al., "Effects of IGF-I on renal function in patients with chronic renal failure" <u>Am. J. Physiol.</u> 264:F917-F922 (1993)
LT	43	O'Shea et al., "Roles of growth hormone and growth factors in the pathogenesis and treatment of kidney disease" <u>Current Opinion in Neph. and Hypertension</u> 2:67-72 (1993)
LT	44	Quigley and Baum, "Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport" <u>J. Clin. Invest.</u> 88:368-374 (1991)

Examiner

Rhyn Deyar, DCO

Date Considered

4-12-96

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449			U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. 943-3	Serial No. 08/447,292
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)					
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
LT	45	Quin et al. <u>New England J. of Medicine</u> 323:1425-1426 (1990)			
LT	46	Rinderknecht and Humbel, "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin" <u>Journal of Biological Chemistry</u> 253(8):2769-2776 (1978)			
LT	47	Rinderknecht and Humbel, "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II" <u>Proc. Natl. Acad. Sci USA</u> 73(7):2365-2369 (1976)			
LT	48	Schalch et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) in type II diabetes mellitus" <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, ed., New York:Elsevier Science Publ. Co. pps. 705-714 (1991)			
LT	49	Schoenle et al., "Recombinant human insulin-like growth factor I(rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance" <u>Diabetologia</u> 34:675-679 (1991)			
LT	50	Underwood et al., "Regulation of somatomedin-c/insulin-like growth factor I by nutrients" <u>Hormone Res.</u> 24:166-176 (1986)			
LT	51	Usala et al., "Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes" <u>New England J. of Medicine</u> 327(12):853-857 (1992)			
LT	52	Van Wyk et al., "The somatomedins: a family of insulinlike hormones under growth hormone control" <u>Recent Prog. Horm. Res.</u> 30:259-318 (1974)			
LT	53	Walker et al., "Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type)" <u>J. Pediatr.</u> 121:641-646 (1992)			
LT	54	Wilton et al., "Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome)" <u>Acta Paediatr Suppl</u> 383:137-141 (1992)			
LT	55	Zenobi et al.; "Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion" <u>J. Clin. Invest.</u> 89:1908-1913 (1992)			
LT	56	Zenobi et al., "Insulin-like growth factor-I improves glucose lipid metabolism in type 2 diabetes mellitus" <u>J. Clin. Invest.</u> 90:2234-2241 (1992)			
Examiner				Date Considered 4-12-96	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Examiner

Phyllis Dawson PhD

Date Considered

4-12-96

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.